DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis
Portfolio Pulse from Benzinga Newsdesk
DURECT Corporation has completed enrollment in its Phase 2b AHFIRM clinical trial investigating larsucosterol for the treatment of severe alcohol-associated hepatitis, reaching its target of 300 patients.
June 07, 2023 | 10:02 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
DURECT Corporation completed enrollment in its Phase 2b AHFIRM clinical trial for larsucosterol, potentially bringing the company closer to a new treatment for alcohol-associated hepatitis.
Completing enrollment in the Phase 2b trial is a significant milestone for DURECT Corporation, as it brings the company closer to potentially having a new treatment for alcohol-associated hepatitis. This news may positively impact the stock price in the short term, as investors may see it as a sign of progress in the company's drug development pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100